Journal
FASEB JOURNAL
Volume 36, Issue 7, Pages -Publisher
WILEY
DOI: 10.1096/fj.202200241RR
Keywords
entacapone; ferroptosis; ischemia; reperfusion; NRF2
Categories
Funding
- Natural Science Foundation of Shanghai (Shanghai Natural Science Foundation) [20ZR140710]
Ask authors/readers for more resources
Entacapone, a specific inhibitor of catechol-O-methyltransferase, has been shown to prevent renal ischemia/reperfusion-induced injury by inhibiting ferroptosis and enhancing antioxidant capacity.
Acute kidney injury (AKI) is a common clinical problem and an efficacious treatment is lacking. Ferroptosis, a newly discovered type of programmed cell death, has been reported to alleviate renal tubular injury in ischemia/reperfusion-induced acute kidney injury (I/R-AKI). Entacapone is a specific inhibitor of catechol-O-methyltransferase, which is used as an adjuvant drug against Parkinson's disease. We demonstrated that entacapone prevents renal I/R injury by inhibiting ferroptosis. Compared with a sham group, entacapone treatment mitigated I/R-induced pathological alterations, improved renal function, and inhibited ferroptosis. In HK-2 cells, entacapone treatment significantly reduced the lipid peroxidation and iron accumulation induced by the ferroptosis inducers erastin and RSL3, and significantly regulated expression of ferroptosis-related proteins. Entacapone upregulates p62 expression and affects the p62-KEAP1-NRF2 pathway, thereby upregulating nuclear translocation of NRF2. This action results in increased expression of the downstream SLC7A11, and significant suppression of oxidative stress and ferroptosis. Our results identify entacapone as a ferroptosis inhibitor that enhances antioxidant capacity. Entacapone may serve as a novel strategy to improve treatment of, and recovery from, I/R-AKI.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available